Pharmaceutical firm Scienture Holdings, Inc. (NASDAQ:SCNX) on Wednesday officially initiated the commercial rollout of Rezenopy, a 10-milligram naloxone hydrochloride nasal spray.
The company has successfully fulfilled its initial purchase orders to pharmaceutical wholesalers across the U.S.
The release marks a significant growth milestone for the holding company, representing the nationwide distribution of its second product to receive federal regulatory approval.
Tackling High-Potency Synthetic Opioids
Rezenopy is currently the highest-dose naloxone nasal spray approved for the U.S. market. Packaged as a single-use device, the 10-milligram dosage is specifically formulated to combat emergencies involving highly potent synthetic opioids.
The treatment enters a critical and growing sector. Recent data shows the domestic naloxone market generated roughly $143 million in annual revenue from 9.8 million units through June 2026.
Strategic Sales And Institutional Reach
Scienture has established a specialized national sales force. The team is targeting a wide range of healthcare providers, including hospitals, pharmacies, rehabilitation facilities, public health agencies, and emergency medical services.
The product’s reach is bolstered by significant commercial payer coverage, which could extend to over 100 million individuals.
Furthermore, Group Purchasing Organization agreements will provide access to more than 5,000 healthcare locations. This institutional access positions the company to potentially capture over 60% of the domestic institutional naloxone market.
The commercialization follows a March 2025 agreement between a Scienture subsidiary and Summit Biosciences Inc., a unit of Kindeva.
That deal secured exclusive domestic rights for Rezenopy, which originally earned regulatory clearance in April 2024.
In June, Scienture announced a U.S. patent covering Rezenopy (naloxone HCl) Nasal Spray 10 mg, with an expiry date of February 5, 2041.
Scienture in May secured $11 million in non-dilutive debt financing to support commercialization and product launch activities of its two FDA-approved products, as well as pipeline execution.
“Moreover, the strengthening of our capital position through this financing will be a catalyst that will help carry us through to profitability, which we anticipate achieving in 2027,” said Narasimhan Mani, President and Co-CEO of Scienture.
SCNX Price Action: Scienture Holdings shares were down 3.03% at $0.39 during premarket trading on Wednesday, according to Benzinga Pro data.
Photo: Billion Photos / Shutterstock
Login to comment